resolver

Liddle, R.A., Goldfine, I.D., Williams, J.A. (1984). Bioassay of plasma
cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol.
Gastroenterology 87, 542-549
Lin, S., Shi, Y.C., Yulyaningsih, E., Aljanova, A., Zhang, L., Macia, L., Nguyen,
A.D., Lin, E.J., During, M.J., Herzog, H., Sainsbury, A. (2009). Critical role of
arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced
reduction in food intake in mice. PLoS One 4, 8488
Lindenbach, B.D, Evans, M.J., Syder, A.J., Wölk, B., Tellinghuisen, T.L., Liu, C.C.,
Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A., Rice, C.M. (2005).
Complete replication of hepatitis C virus in cell culture. Science 309, 623-626
Lukasiewicz, E., Hellstrand, K., Westin, J., Ferrari, C., Neumann, A.U., Pawlotsky,
J.M., Schalm, S.W., Zeuzem, S., Veldt, B.J., Hansen, B.E., Verhey-Hart, E.,
Lagging, M. (2007). Predicting treatment outcome following 24 weeks peginterferon
alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-
RNA at day 0, day 22, day 29, and week 6. Hepatology 45, 258-259
Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli,
F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito,
F., Andriulli, A. (2005). Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in
HCV genotype 2 or 3. N Engl J Med. 352, 2609-2617
Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M.,
Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001).
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin
for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965
Marco, J., Zulueta, M.A., Correas, I., Villanueva, M.L. (1980). Reduced pancreatic
polypeptide secretion in obese subjects. J Clin Endocrinol Metab. 50, 744-747
Major, M.E., Feinstone, S.M. (1997). The molecular virology of hepatitis C.
Hepatology 25, 1527-1538
78